NCT04831567 (MIBNET) is a Phase 2 clinical trial of MIBG-I131 in Neuroendocrine Tumors, sponsored by AC Camargo Cancer Center.

Who is sponsoring NCT04831567?

NCT04831567 is sponsored by AC Camargo Cancer Center.

What drugs are being tested in NCT04831567?

Interventions in NCT04831567: MIBG-I131.

What condition does NCT04831567 study?

NCT04831567 studies Neuroendocrine Tumors.

Is NCT04831567 still recruiting?

NCT04831567 is currently withdrawn. Last updated 19 May 2022.

Last reviewed 2022-05-19 · How we verify

NCT04831567: MIBNET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors

Withdrawn Phase 2 Last updated 19 May 2022

What this trial tests

Phase 2 trial testing MIBG-I131 in Neuroendocrine Tumors. Withdrawn.

Timeline

4 February 2021

Primary endpoint
13 May 2022

13 May 2022

Quick facts

Lead sponsor	AC Camargo Cancer Center
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	4 February 2021
Primary completion	13 May 2022
Estimated completion	13 May 2022
Sites	1 location across Brazil

Drugs / interventions tested

MIBG-I131

Conditions studied

Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →

Sponsor

AC Camargo Cancer Center — full company profile →

Who can join

18 and older, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, unicentric, single-stage, phase 2 clinical study of therapeutic metaiodobenzylguanidine (MIBG) for patients with metastatic well-differentiated neuroendocrine tumors and radiological progression or intolerance after standard lines of treatment and with MIBG positive scan.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.
Richter S, Steenblock C, Fischer A, Lemm S, et al · · 2024 · cited 8× · PMID 38164150 · DOI 10.7150/thno.87345

Verify or expand the search:

Other recruiting trials for Neuroendocrine Tumors

Currently open trials in the same condition.

NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting

Other AC Camargo Cancer Center trials

Trials by the same sponsor.

NCT07285356 — Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy · NA · recruiting
NCT07268846 — Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery · NA · recruiting
NCT06793137 — Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT06472388 — Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors · Phase 2 · recruiting
NCT06207487 — Evaluation of Herpes Zoster Characteristics and Costs in Cancer Population. · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04831567 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AC Camargo Cancer Center
Last refreshed: 19 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04831567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing